Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression

Stem Cells

Volumn 27, Issue 8, 2009, Pages 1954-1962

  Ren, Guangwen ^a   Su, Juanjuan ^b,c   Zhang, Liying ^a   Zhao, Xin ^a   Ling, Weifang ^a   L'Huillie, Andrew ^a   Zhang, Jimin ^a   Lu, Yongqing ^b,c   Roberts, Arthur I ^a   Ji, Weizhi ^c   Zhang, Huatang ^c   Rabson, Arnold B ^a,d   Shi, Yufang ^a,b,c  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c KUNMING INSTITUTE OF ZOOLOGY   (China)

^d CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Chemokine; Immunosuppression; Indoleamine 2,3 dioxygenase; Mesenchymal stem cells; Nitric oxide

Indexed keywords

CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; NITRIC OXIDE; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ARTICLE; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MESENCHYMAL STEM CELL; MONKEY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPECIES DIFFERENCE;

ANIMALS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; MACACA MULATTA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; SPECIES SPECIFICITY;

EID: 69249119079     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.118     Document Type: Article

References (42)

1. Xu G, Zhang L, Ren G et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 2007;17:240-248.
2. Le Blanc K, Frassoni F, Ball L et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. Lancet 2008;371:1579-1586.
3. Le Blanc K, Rasmusson I, Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-1441.
4. Burt RK, Loh Y, Pearce W et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008;299:925-936.
5. Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independent of regulatory T cells. Stem Cells 2008;26:1913-1919.
6. Ren G, Zhang L, Zhao X et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008;2:141-150.
7. Nasef A, Chapel A, Mazurier C et al. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr 2007;13:217-226.
8. Di Nicola M, Carlo-Stella C, Magni M et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002;99:3838-3843.
9. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005;105:1815-1822.
10. Sato K, Ozaki K, Oh I et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007;109:228-234.
11. Meisel R, Zibert A, Laryea M et al. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004;103:4619-4621.
12. Djouad F, Plence P, Bony C et al. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003;102:3837-3844.
13. Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992;258:1898-1902.
14. Edwards TM, Rickard NS. New perspectives on the mechanisms through which nitric oxide may affect learning and memory processes. Neurosci Biobehav Rev 2007;31:413-425.
15. Murad F. Shattuck Lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med 2006;355:2003-2011.
16. Niedbala W, Cai B, Liew FY. Role of nitric oxide in the regulation of T cell functions. Ann Rheum Dis 2006;65 Suppl 3:iii37-iii40.
17. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med 2004;10:15-18.
18. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007;7:31-40.
19. Munn DH, Sharma MD, Baban B et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 2005;22:633-642.
20. Forouzandeh F, Jalili RB, Germain M et al. Differential immunosuppressive effect of indoleamine 2,3-dioxygenase (IDO) on primary human CD4(+) and CD8(+) T cells. Mol Cell Biochem 2008;309:1-7.
21. Wang J, Simonavicius N, Wu X et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J Biol Chem 2006;281:22021-22028.
22. Ren G, Su J, Zhao X et al. Apoptotic cells induce immunosuppression through dendritic cells: Critical roles of IFN-gamma and nitric oxide. J Immunol 2008;181:3277-3284.
23. Shi Y, Kornovski BS, Savani R et al. A rapid, multiwell colorimetric assay for chemotaxis. J Immunol Methods 1993;164:149-154.
24. Schneemann M, Schoedon G. Species differences in macrophage NO production are important. Nat Immunol 2002;3:102.
25. Jungi TW, Adler H, Adler B et al. Inducible nitric oxide synthase of macrophages. Present knowledge and evidence for species-specific regulation. Vet Immunol Immunopathol 1996;54:323-330.
26. Ryan JM, Barry F, Murphy JM et al. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007;149:353-363.
27. Spaggiari GM, Capobianco A, Abdelrazik H et al. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: Role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008;111:1327-1333.
28. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007;117:1147-1154.
29. Grohmann U, Orabona C, Fallarino F et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-1101.
30. Mellor AL, Munn DH. IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 2004;4:762-774.
31. Hulkower K, Brosnan CF, Aquino DA et al. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol 1993;150:2525-2533.
32. Uyttenhove C, Pilotte L, Theate I et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-1274.
33. Liu H, Liu L, Fletcher BS et al. Sleeping Beauty-based gene therapy with indoleamine 2,3-dioxygenase inhibits lung allograft fibrosis. FASEB J 2006;20:2384-2386.
34. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007;7:610-621.
35. Mackler AM, Barber EM, Takikawa O et al. Indoleamine 2,3-dioxygenase is regulated by IFN-gamma in the mouse placenta during Listeria monocytogenes infection. J Immunol 2003;170:823-830.
36. Chon SY, Hassanain HH, Gupta SL. Cooperative role of interferon regulatory factor 1 and p91 (STAT1) response elements in interferon-gamma- inducible expression of human indoleamine 2,3-dioxygenase gene. J Biol Chem 1996;271:17247-17252.
37. Fujigaki S, Saito K, Sekikawa K et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol 2001;31:2313-2318.
38. Weinberg JB, Misukonis MA, Shami PJ et al. Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): Analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 1995;86:1184-1195.
39. Albina JE. On the expression of nitric oxide synthase by human macrophages. Why NO? NO? J Leukoc Biol 1995;58:643-649.
40. Denis M. Human monocytes/macrophages: NO or no NO? J Leukoc Biol 1994;55:682-684.
41. Geller DA, Lowenstein CJ, Shapiro RA et al. Molecular cloning and expression of inducible nitric oxide synthase from human hepatocytes. Proc Natl Acad Sci U S A 1993;90:3491-3495.
42. Linscheid P, Schaffner A, Blau N et al. Regulation of 6-pyruvoyltetrahydropterin synthase activity and messenger RNA abundance in human vascular endothelial cells. Circulation 1998;98:1703-1706.